FindTrial
Sign In

Insulin glargine/Lixisenatide (HOE901/AVE0010)

DRUG7 trials

Sponsors

Sanofi

Conditions

Type 2 DiabetesType 2 Diabetes Mellitus

Phase 3

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
CompletedNCT02058160
SanofiType 2 Diabetes
Start: 2014-01-31End: 2015-07-31Updated: 2017-05-09
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
CompletedNCT02749890
SanofiType 2 Diabetes Mellitus
Start: 2016-05-09End: 2018-05-31Updated: 2020-06-16
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
CompletedNCT02752828
SanofiType 2 Diabetes Mellitus
Start: 2016-05-23End: 2018-03-12Updated: 2020-06-16
Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
CompletedNCT02752412
SanofiType 2 Diabetes Mellitus
Start: 2016-05-17End: 2018-10-04Updated: 2020-06-16
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)
CompletedNCT03529123
SanofiType 2 Diabetes Mellitus
Start: 2018-06-19End: 2019-11-25Updated: 2022-04-25
Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
CompletedNCT03798054
SanofiType 2 Diabetes Mellitus
Start: 2019-02-15End: 2021-03-01Updated: 2022-07-19
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
CompletedNCT03798080
SanofiType 2 Diabetes Mellitus
Start: 2019-02-19End: 2020-12-01Updated: 2022-07-19

Related Papers

<scp>iGlarLixi</scp> effectively reduces residual hyperglycaemia in Chinese people with type 2 diabetes on basal insulin: A post hoc analysis of the <scp>LixiLan</scp> ‐L‐ <scp>CN</scp> study
Diabetes Obesity and Metabolism2024-10-032 citations
Improved glycaemic control and weight benefit with <scp>iGlarLixi</scp> versus insulin glargine 100 U/ <scp>mL</scp> in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the <scp>LixiLan‐L‐CN</scp> randomized controlled trial
Diabetes Obesity and Metabolism2022-06-2825 citations
850-P: Greater HbA1c Reduction with iGlarLixi vs. Insulin Glargine and Lixisenatide Regardless of Levels at Screening: Subgroup Analysis of the LixiLan-O Asia Pacific Trial
Diabetes2022-05-31
Efficacy and safety benefits of <scp>iGlarLixi</scp> versus insulin glargine 100 U/ <scp>mL</scp> or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The <scp>LixiLan‐O‐AP</scp> randomized controlled trial
Diabetes Obesity and Metabolism2022-04-1929 citations
iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A <i>post‐hoc</i> analysis of the LixiLan JP‐L trial
Journal of Diabetes Investigation2021-05-045 citations
Benefits of the fixed‐ratio combination of insulin glargine 100 units/ <scp>mL</scp> and lixisenatide ( <scp>iGlarLixi</scp> ) in Japanese people with type 2 diabetes: A subgroup and time‐to‐control analysis of the <scp>LixiLan JP</scp> phase 3 trials
Diabetes Obesity and Metabolism2020-07-067 citations
Efficacy and safety of insulin glargine/lixisenatide fixed‐ratio combination ( <scp>iGlarLixi</scp> 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26‐week, open‐label, multicentre study: The <scp>LixiLan JP‐O2</scp> randomized clinical trial
Diabetes Obesity and Metabolism2020-04-1535 citations
Efficacy and safety of insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP‐L randomized clinical trial
Diabetes Obesity and Metabolism2020-02-1933 citations
Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis.
2019-12-1717 citations
Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.
2019-11-263 citations
Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.
2019-07-292 citations
EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES.
2019-06-26
Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world
BMJ Open Diabetes Research & Care2019-03-013 citations
Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.
2019-01-112 citations
Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L.
2018-09-141 citations
A1C Target Attainment in Patients with T2D Receiving iGlarLixi Who Reach PPG and FPG Targets in the Lixilan-L Trial
Diabetes2018-06-222 citations
Relationship of Ethnicity to Clinical Outcomes in iGlarLixi-Treated Patients with Type 2 Diabetes
Diabetes2018-06-221 citations
Low incidence of gastrointestinal adverse events over time with a fixed‐ratio combination of insulin glargine and lixisenatide versus lixisenatide alone
Diabetes Obesity and Metabolism2018-06-2021 citations
iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L.
2017-11-168 citations
Consistent findings in glycaemic control, body weight and hypoglycaemia with <scp>iGlarLixi</scp> (insulin glargine/lixisenatide titratable fixed‐ratio combination) vs insulin glargine across baseline <scp>HbA1c</scp> , <scp>BMI</scp> and diabetes duration categories in the <scp>LixiLan‐L</scp> trial
Diabetes Obesity and Metabolism2017-04-0626 citations